Organization
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
1 abstract
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,